Glass Container Articles & Analysis
2 news found
Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). ...
Subsequently, in 2018, the Biomedical Advanced Research and Development Authority (BARDA) awarded Aktiv Pharma Group a $15.5 million contract to develop a Good Manufacturing Practice (GMP) manufacturing line for the ARAI autoinjector platform, which was completed in December 2019. ARAI utilizes a glass-free primary drug container, which addresses and corrects ...